On the 14th and 15th of April, one of the largest Bulgarian cultural events for the last decades will take place in Paris. Then, the exhibition “Epopee of Thracian Kings, Archaeological Discoveries in Bulgaria” will open in the Louvre, showing all the opulence of one of the most ancient and creative civilisations in our land. It is expected that the exhibition which will run until the 20th of July will be seen by 4 mln potential visitors.

Dear Media, please inform the public in accordance with the rules of journalism. Four Rules of Journalism: always tell the truth act independently minimize harm be accountable Tribestan® is a herbal product obtained by an original technology from the aerial parts of the plant Tribulus terrestris L. TribulusTerrestris (Tribulus) is a medicinal herb with long tradition and wide use. The name of the herb is derived from the Latin meaning of the word Tribulus.

Georg Kell, Executive Director of the UN Global Compact, will be present at the event organised by the Bulgarian Global Compact Network (BGCN). RESPONSIBLE CHOICE 2015 is a BGCN member companies' project as a response to significant social issues. "We believe that by our responsible corporate behaviour and standards we follow and implement in our everyday activities, we are changing our common reality.

The start of the RESPONSIBLE CHOICE Project of Global Compact Network Bulgaria (GCNB) with the United Nations was reflected in the official website of Global Compact. Its announcement was attended by Mr. Georg Kell, Executive Director of Global Compact, who signed also the annual Memorandum of Understanding with the Bulgarian companies. The leading companies in the initiative include Sopharma AD, Overgas Inc. AD, TechnoLogistica AD, ContourGlobal Maritsa Iztok 3 AD, Mobiltel AD and VUZF (University of Finance, Business and Enterpreneurship).

Rick Stewart didn’t know about the laburnum trees growing in Bulgaria — and their potential to produce a drug for quitting smoking — back when he was the chief executive of the pharmaceutical company Amarin. He was too deep inside the drug industry, a place often criticized for its short-sighted focus on profits. He had to fail first. Only then could he spot the opportunity in those yellow-flowering trees. Now, with the help of the National Institutes of Health, Stewart is trying to introduce the laburnum-derived drug to the U.S. market.